ReviewSchizophrenia bulletin2009
Secondary effects of antipsychotics: women at greater risk than men.
Review in Schizophrenia bulletin, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 5 syntheses or guidelines pooled it, 189 citations in OpenAlex.
- Unravelling the role of the gut microbiome in antipsychotic-induced weight gain and metabolic dysfunction in humans and rodents: A systematic review.Dialogues in clinical neuroscience · 2026Pooled it
- Sex differences in schizophrenia: symptomatology, treatment efficacy and adverse effects.Frontiers in psychiatry · 2025Pooled it
- Schizophrenia and type 2 diabetes risk: a systematic review and meta-analysis.Frontiers in endocrinology · 2024Pooled it
- Evidence-Based Recommendations for the Pharmacological Treatment of Women with Schizophrenia Spectrum Disorders.Current psychiatry reports · 2023Pooled it
- Changes in body weight and psychotropic drugs: a systematic synthesis of the literature.PloS one · 2012Pooled it
- Orlistat for the treatment of antipsychotic-induced weight gain: an eight-week multicenter, randomized, placebo-controlled, double-blind trial.Lipids in health and disease · 2024Trial
- Trial
- A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers.PloS one · 2011Trial
- Antipsychotic Medication Preferences: A Large-Scale Survey.Pharmacopsychiatry · 2026Article
- Risperidone induces osteoporosis and neuropsychiatric treatment resistance via SMPD1-lysosome-mediated ferroptosis: dual rescue by active vitamin D analog ED-71.Journal of advanced research · 2026Article
- Hyperhomocysteinemia in chronic schizophrenia: prevalence, clinical correlates, and paradoxical associations with symptom severity.European archives of psychiatry and clinical neuroscience · 2026Article
- Sexual Function and Depressive Symptoms in Metformin-Treated Women with Drug-Induced Hyperprolactinemia and Different Vitamin D Status: A Pilot Study.Pharmaceutics · 2026Article
- Women with Schizophrenia: Beyond Psychosis.Community mental health journal · 2025Article
- Article
- Combination of UGT1A1 polymorphism and baseline plasma bilirubin levels in predicting the risk of antipsychotic-induced dyslipidemia in schizophrenia patients.Schizophrenia (Heidelberg, Germany) · 2024Article
- First generation antipsychotic-associated serious adverse events in women: a retrospective analysis of a pharmacovigilance database.International journal of clinical pharmacy · 2024Article
- Sex differences in autonomic adverse effects related to antipsychotic treatment and associated hormone profiles.Schizophrenia (Heidelberg, Germany) · 2024Article
- Challenges in diagnosis, treatment and coordination of care of menstrual psychosis.BMJ case reports · 2023Article
- Sex differences in prevalence and clinical correlates of insomnia in Chinese patients with chronic schizophrenia.European archives of psychiatry and clinical neuroscience · 2023Article
- Sex and pubertal influences on the neurodevelopmental underpinnings of schizophrenia: A case for longitudinal research on adolescents.Schizophrenia research · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextThe health burden of antipsychotic medication is well known, but the disproportionate effect on women as compared with men is underappreciated.
objectiveThe goal of this article is preventive--to better inform clinicians so that the risks to women and to their offspring can be diminished.
methodAll PubMed sources in which the search term gender (or sex) was linked to a side effect of antipsychotic medication were reviewed.
resultThere is general agreement in the literature on women's increased susceptibility to weight gain, diabetes, and specific cardiovascular risks of antipsychotics, with less consensus on malignancy risks and risks to the fetus. Cardiovascular death, to which men are more susceptible than women, is disproportionately increased in women by the use of antipsychotics. Sedating antipsychotics raise the risk of embolic phenomena during pregnancy, and postpartum. Prolactin-elevating drugs suppress gonadal hormone secretion and may enhance autoimmune proclivity.
conclusionsClinicians need to be aware of the differential harm that women (and their offspring) can incur from the side effects of antipsychotics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.